Vietnam's growing investment in biotechnology, genomics, precision medicine and advanced biomedical research is creating an emerging market for multiomics technologies, which combine multiple layers of biological information to provide a more complete understanding of disease.
While dedicated Vietnam market research exists, publicly available data does not disclose a reliable country-level revenue figure. Based on Vietnam's developing life-sciences ecosystem and Asia-Pacific market benchmarks, the Vietnam Multiomics Market is estimated at approximately US$20–30 million in 2025 and could reach US$45–65 million by 2030.
What is multiomics?
Traditional biomedical research often examines one layer of biology at a time.
Genomics studies DNA and genetic variation. Transcriptomics examines RNA and gene expression. Proteomics analyses proteins. Metabolomics examines metabolites and biochemical processes, while epigenomics investigates changes that influence gene activity without altering the underlying DNA sequence.
Multiomics combines these different datasets.
By integrating information across several biological layers, researchers can develop a much more detailed understanding of how genes, proteins, metabolites and cellular processes interact in health and disease.
Vietnam-specific market research already identifies genomics, transcriptomics, proteomics, metabolomics and integrated-omics platforms as distinct segments of the country's developing multiomics market.
Precision medicine drives adoption
One of the most important applications is precision medicine.
Patients with apparently similar diseases can have very different molecular characteristics and may therefore respond differently to the same treatment.
Multiomics allows researchers to combine different types of molecular information to identify these differences and potentially develop more personalised approaches to diagnosis and treatment.
Vietnam's wider precision-medicine sector is already substantial. IMARC Group values the Vietnam Precision Medicine Market at US$11.6 billion in 2025 and forecasts it to reach US$17.0 billion by 2034. Gene sequencing, bioinformatics, big-data analytics and companion diagnostics are all included within this ecosystem.
Oncology represents a major opportunity
Cancer is likely to be one of the most important applications for multiomics.
A tumour can be examined simultaneously at genomic, transcriptomic, proteomic and metabolic levels, potentially revealing information that would remain hidden if researchers examined DNA alone.
This can help scientists identify biomarkers, molecular subtypes, therapeutic targets and mechanisms of treatment resistance.
Vietnam-specific multiomics research consequently identifies oncology alongside immunology, neurology and cell biology as major application categories.
Single-cell multiomics moves analysis to a new level
One of the fastest-developing areas is single-cell multiomics.
Traditional analysis may examine biological information averaged across thousands or millions of cells. Single-cell technologies allow scientists to investigate individual cells and identify important differences between them. This is particularly valuable in areas such as cancer and immunology, where apparently similar cells may behave very differently.
Grand View Research identifies single-cell multiomics as the fastest-growing type within the Asia-Pacific market, while Vietnam already has dedicated market research covering single-cell genomics, proteomics, transcriptomics and metabolomics.
AI and bioinformatics become essential
Multiomics also creates an enormous data challenge.
A single genomic study can generate vast quantities of information. Combining genomics with transcriptomics, proteomics and metabolomics multiplies that complexity.
Bioinformatics, artificial intelligence and machine learning are therefore becoming essential components of the multiomics ecosystem.
AI can help researchers identify patterns across complex biological datasets, connect molecular changes with disease characteristics and prioritise potential biomarkers or drug targets.
This means the commercial opportunity extends beyond laboratory instruments into bioinformatics software, cloud computing, AI, data-analysis services and biological databases.
Pharmaceutical R&D creates another growth market
Multiomics is increasingly important in drug discovery and clinical development.
Pharmaceutical and biotechnology companies can use integrated biological data to identify disease pathways, discover new therapeutic targets, understand why drugs succeed or fail and identify which patients are most likely to respond to particular treatments.
Vietnam's dedicated multiomics research identifies pharmaceutical and biotechnology companies alongside academic and research institutions as principal end users.
Vietnam's broader biotechnology industry provides an increasingly strong foundation. IMARC Group values the Vietnam Biotechnology Market at US$3.41 billion in 2025, forecasting it to reach US$8.86 billion by 2034, representing annual growth of 10.87%.
Multiomics services grow particularly quickly
Not every hospital, pharmaceutical company or research institution needs to own sophisticated sequencing, mass-spectrometry and computational infrastructure.
This is creating rapid growth in outsourced multiomics services.
Grand View Research values the Asia-Pacific Multiomics Services Market at US$332.2 million in 2025, forecasting it to reach US$1.39 billion by 2033, at a 19.8% CAGR. Data-analysis services are expected to be among the fastest-growing segments.
For Vietnam, this creates opportunities for contract research organisations, sequencing laboratories, proteomics laboratories, bioinformatics companies and specialist analytical-service providers.
Asia-Pacific market approaches US$2 billion
The regional market provides the strongest benchmark for Vietnam's potential.
Grand View Research estimates that the Asia-Pacific Multiomics Market generated US$529.8 million in 2025 and will reach US$1.96 billion by 2033, representing a 17.8% CAGR between 2026 and 2033. Asia-Pacific is expected to be the world's fastest-growing regional multiomics market.
Globally, Grand View Research values multiomics at US$3.1 billion in 2025, rising to US$9.8 billion by 2033.
Other current forecasts show a similar trajectory. The Business Research Company estimates US$3.85 billion in 2025, rising to US$8.07 billion by 2030, at a 15.6% CAGR, while identifying Asia-Pacific as the fastest-growing region.
An emerging opportunity across Vietnam's life-sciences sector
For Vietnam, multiomics sits at the intersection of several rapidly developing healthcare and life-sciences technologies.
The commercial ecosystem encompasses next-generation sequencing, mass spectrometry, genomics, proteomics, metabolomics, single-cell analysis, laboratory automation, bioinformatics, AI, cloud computing and specialist research services.
As Vietnam strengthens its capabilities in biotechnology, pharmaceutical R&D, clinical research and precision medicine, demand for technologies capable of integrating multiple layers of biological information is likely to increase.
With the wider Asia-Pacific multiomics market growing at almost 18% annually, Vietnam represents an early-stage but potentially fast-growing opportunity for laboratory technology companies, sequencing businesses, pharmaceutical and biotechnology companies, CROs, bioinformatics providers and research organisations.